...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Haematology >Treatment of advanced stage Hodgkin lymphoma - it's all about risk-benefit
【24h】

Treatment of advanced stage Hodgkin lymphoma - it's all about risk-benefit

机译：晚期霍奇金淋巴瘤的治疗-一切都与风险收益有关

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In formulating treatment protocols for Hodgkin lymphoma (HL), one will find a wealth of randomized clinical trials trying to define what the standard of care should be. Yet, more than ever, the answer to the question of which therapy should be initiated in a patient with newly diagnosed advanced stage HL is not as straight forward as it should be. For all the many publications comparing the combination of bleomycin, etoposide, adriamycin, cyclophosphamide, vin-cristine, procarbazine and prednisolone (BEACOPP) versus adriamycin, bleomycin, vinblastine and dacarbazine (ABVD), there have been none that have directly compared ABVD versus eight cycles of escalated BEACOPP (8 x B_(esc)), which, up until this month's publication in the Lancet (Engert et al, 2012) was still considered the standard of treatment by the German Hodgkin Study Group (GHSG).
机译：在制定霍奇金淋巴瘤（HL）的治疗方案时，人们会发现大量随机临床试验，试图确定应该采用的护理标准。然而，对于新诊断的晚期HL患者应开始哪种治疗的问题，答案比以往任何时候都没有那么直接。对于将博来霉素，依托泊苷，阿霉素，环磷酰胺，长春新碱，普卡巴嗪和泼尼松龙（BEACOPP）与阿霉素，博来霉素，长春碱和达卡巴嗪（ABVD）的组合进行比较的所有出版物，尚无直接比较ABVD与八种比较的出版物逐步升级的BEACOPP（8 x B_（esc））周期，直到本月在Lancet上发表（Engert等，2012），德国霍奇金研究小组（GHSG）仍将其视为治疗标准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号